Medial artery calcification increases neointimal hyperplasia after balloon injury

Andre P. Marshall1, Weifeng Luo1, Xue-lin Wang1,2, Tonghui Lin1,2, Yujun Cai2 & Raul J. Guzman1,2

Arterial calcification predicts accelerated restenosis after angioplasty and stenting. We studied the effects of calcification on neointimal hyperplasia after balloon injury in the rat carotid. Arterial calcification was induced by subcutaneous injection of vitamin D3 or by adventitial application of calcium chloride. After balloon catheter injury, neointimal hyperplasia was significantly increased in rats with medial calcification compared with controls. Neointimal cell proliferation in calcified arteries as assessed by proliferating cell nuclear antigen (PCNA) staining was also higher. In calcified arteries, bone morphogenetic protein 2 (BMP-2) levels were increased at the time of injury suggesting a possible explanation for the altered responses. In vascular smooth muscle cells (SMCs) grown under calcifying conditions, stimulation with BMP-2 significantly increased cell proliferation, however, this did not occur in those grown under non-calcifying conditions. These data suggest that neointimal hyperplasia is accelerated in calcified arteries and that this may be due in part to increased BMP-2 expression in medial SMCs. Treatments aimed at inhibiting restenosis in calcified arteries may differ from those that work in uncalcified vessels.

Endovascular interventions have increasingly been used as first-line therapies for patients with symptomatic arterial disease1,2. The durability of such procedures, however, is limited by restenosis that is thought to affect at least 17% of coronary, 25% of superficial femoral, and 40% of tibial endovascular procedures within 1 year3–5. One factor that has increasingly been associated with accelerated restenosis rates is the amount of calcification in the arterial wall. In the coronary arteries, calcified lesions are associated with increased restenosis risk, and this remains true with drug eluting stents6–8. In the superficial femoral artery (SFA), calcification as seen on fluoroscopy predicts a higher failure rate and increased need for re-intervention9. The mechanisms that link increased calcification with restenosis, however, have not been fully explored.

Arterial calcification is generally divided into two forms that involve either the atherosclerotic intima or the media. Medial artery calcification (MAC) is most prominent in the settings of diabetes and renal disease10. It is related to abnormalities in bone-mineral metabolism, and the mechanisms that control it are just beginning to be understood11. MAC is associated with increased cardiovascular event rates including amputation12. The relationship between medial artery calcification and increased failure rates after endovascular interventions has not been defined.

Investigators, including us, have previously demonstrated that bone morphogenetic proteins (BMPs) and their signaling molecules can exert control over smooth muscle cell (SMC) migration, proliferation, and expression of phenotypic markers13–18. In calcifying arteries, medial smooth muscle cells undergo transformation to a more bone-like cell, and BMP expression is increased19. We thus sought to investigate whether neointimal accumulation was different after balloon injury in normal versus calcifying arteries. We further explored the effects of BMP-2 on proliferation in normal SMCs and in those undergoing phosphate-induced osteogenic transformation.

1Division of Vascular Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. 2Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Correspondence and requests for materials should be addressed to R.J.G. (email: rjguzman@bidmc.harvard.edu)
Results

**Increased neointimal hyperplasia in vitamin D3-injected rats.** We first assessed the effects of vitamin D3 administration on the rat carotid. Histologic assessment of carotid arteries at 2 weeks after vitamin D3 injection showed calcium calcification in the arterial wall as demonstrated by Von Kossa staining. There was also extensive cell drop out and elastin destruction. At this time point, before balloon catheter injury, calcification was localized to the medial layer and no intimal accumulation had developed. Carotid calcium levels were significantly increased in vitamin D3-injected rats compared with vehicle-injected controls. (Fig. 1A,B). Vitamin D levels in serum were nearly 3-fold higher in vitamin D3 compared with vehicle-injected rats. (Fig. 1C).

Balloon injury was next performed to induce neointimal formation in the left carotid artery. After three weeks, morphometric analysis of VVG stained sections showed that carotid arteries from vitamin D3-injected rats had significantly more neointimal hyperplasia than those from rats injected with vehicle, (1.25±0.16 in vitamin D3 versus 0.417±0.08 vehicle, p=0.038, Fig. 2A–E). In response to balloon injury, the number of proliferating cells was also significantly increased in the intima of calcified arteries compared with controls (65.2±5.1 versus 38.5±6.8 cells/high power field, P<0.001, Fig. F,G).

**Neointimal hyperplasia is increased in arteries with CaCl2-induced calcification.** Vitamin D3 is known to promote SMC proliferation in vitro and this is mediated in part by upregulation of VEGF20,21. Its levels remain elevated for at least 2 weeks after administration in rats (Fig. 1C). In order to determine whether neointimal formation is increased in calcified carotid arteries in the setting of normal Vitamin D3 levels, we used a second model of medial calcification induced by adventitial application of CaCl2. In this model, calcification is induced by painting the external surface of the dissected carotid artery with a solution containing calcium chloride. Arteries treated similarly but painted with normal saline solution served as controls. Adventitial application of CaCl2 resulted in calcium deposition primarily localized to the outer layers of the media (Fig. 3).

In arteries harvested 2 weeks after balloon injury, there was persistent calcification noted in the outer layers of the media (Fig. 4A). Morphometric analysis demonstrated significantly increased neointimal formation in carotids from the CaCl2 group than from those in the control group. (Fig. 4A–E).

**BMP-2 is increased in calcifying carotid arteries even without injury.** We next assessed whether calcifying carotid arteries had increased BMP expression and further, whether this could explain the increased proliferation seen in neointimal cells. In carotid arteries from rats with elevated vitamin D3 levels, there was significant BMP-2 staining in calcified areas whereas there was minimal baseline expression in controls (Fig. 5A). The levels of BMP-2 mRNA and protein in carotid arteries were also significantly increased in vitamin D3-injected rats (Fig. 5B,C). These results advance the possibility that increased BMP-2 levels seen in calcifying arteries might serve to promote SMC proliferation leading to increased neointimal accumulation. To further address if elevated BMP-2 in calcified areas could contribute to cell proliferation, we performed immunohistochemistry staining for the proliferation marker PCNA in carotid arteries from vitamin D3 and vehicle-treated rats. As shown in Fig. 5D, after vitamin D3 injection, elastic fibers were destroyed, and calcium deposits were seen along the elastic lamina. Concomitantly, cell proliferation was increased in calcifying arteries (Fig. 5D,E). However, neointima formation in these calcified but uninjured vessels was not observed.
BMP-2 promotes proliferation in calcifying SMCs. We next evaluated the effects of increased BMP-2 levels on calcifying SMCs in culture. Cells were induced to calcify by stimulation with inorganic phosphate (Pi). SMCs grown in calcification medium showed significantly elevated calcium deposition and ALP levels (Fig. 6A). We then exposed SMCs to exogenous BMP-2 added to the medium, or the positive control PDGF. We found that both calcified and non-calcified SMCs had a strong response to PDGF. In cells grown in normal medium, BMP-2 had no effect on proliferation. In calcifying cells, however, BMP-2 was able to significantly stimulate proliferation (Fig. 6C,D). To test whether the effects we observed were BMP dependent, we added the secreted BMP inhibitor Noggin that works to prevent binding of BMPs to their receptors. We found that proliferation of calcifying SMCs was reversed by addition of Noggin (Fig. 6E,F).

Discussion

The main finding of the present work is that neointimal hyperplasia is increased in arteries with medial calcification. It was associated with increased intimal cell proliferation and medial BMP-2 expression. Cultured SMCs respond more robustly to BMP-2 when grown in calcification medium than controls cells. This suggests that upregulated BMP-2 expression in calcified arteries may promote neointimal proliferation and worsen restenosis after catheter-based interventions. Such findings may provide insight into why patients with higher arterial calcification scores have worse outcomes after endovascular interventions.

Restenosis continues to limit the durability of coronary and peripheral vascular interventions. It is related to excessive proliferation of neointimal cells leading to hemodynamically significant stenosis at sites of vascular injury. In the coronary arteries, increased target lesion revascularization (29.8% vs. 9.8%; $P = 0.020$), and
Figure 3. Medial calcification is induced in rat carotid arteries after application of CaCl₂. Male SD rats were subjected to adventitial application of 0.12 M calcium chloride (CaCl₂) in left carotid artery. One week later, carotid arteries were stained with HE. Calcium deposits were examined using Von Kossa staining. Arrows show calcium deposits.

Figure 4. Intimal hyperplasia is increased in arteries calcified by external application of CaCl₂ in response to balloon injury. Male SD rats were subjected to adventitial application of 0.12 M calcium chloride (CaCl₂) to the left carotid artery and then balloon injury was performed 1 week later. After 14 days, arteries were harvested for histological staining and morphometric analysis. (A) HE staining for morphology; VVG staining for elastin fiber; Von Kossa staining for calcium deposits. (B–E) Morphometric analysis showing area of the lumen, intima, media, and the intima/media (I/M) ratio in rats with normal carotid arteries (saline, n = 30) and calcified arteries after application with CaCl₂ (n = 33). L, lumen; M, media; A, adventitial. Arrows show calcium deposits. Values are mean ± SEM. *P < 0.05.
restenosis (39.5% vs. 17.0%; \( P = 0.029 \)) were seen in calcified versus non-calcified vessels. In a small observational study, there was a significant positive correlation between lesion calcium score and in-stent late lumen loss at 8 months in patients following sirolimus-eluting stent implantation (\( r = 0.47, p < 0.01 \)). Similar associations have been identified after interventions in the superficial femoral artery. The mechanisms responsible for these associations, however, have not been identified.

We initially used a model of medial calcification induced by injecting high doses of vitamin D\(_3\) in rats. Vitamin D\(_3\) is a fat-soluble secosteroid with significant effects on calcium and phosphate homeostasis. The model is characterized by increases in serum calcium and phosphate, and extensive ectopic calcification of elastin containing structures. We found that intimal development after balloon injury was increased in calcified compared with non-calcified arteries. One possibility is that vitamin D\(_3\) directly provoked VSMC proliferation. It was previously found that rats fed a low dose of vitamin D\(_3\) in a concentration that did not induce medial calcification had increased intimal hyperplasia compared with controls. Studies on the effects of vitamin D\(_3\) on SMC proliferation have yielded contradictory findings, and this is likely because its effects are dependent on the specific conditions and state of SMCs grown in culture. For example, Mitsuhashi with others found that 1,25-(OH)\(_2\)D\(_3\) increased proliferation in quiescent SMCs but decreased it in cells that were not quiescent. Several investigators have shown stimulatory effects of vitamin D\(_3\) on SMC proliferation, and taken together, they suggest that these effects are dependent on binding to its intracellular receptor and release of VEGF via p38 activation.
Others have shown minimal or inhibitory effects related to either suppression of EGF, or through suppressed endothelin-induced SMC proliferation through inhibition of CDK2 activity and through a Cdc25A-dependent mechanism33–35. Moreover, it has also been shown that 1alpha, 25-(OH)2D3 induces VSMC migration independent of gene transcription via the PI3 kinase pathway36. Our results showed that SMC proliferation was increased in calcified and uninjured carotid arteries from vitamin D3-injected rats, however, there was no neointima formation observed in these vessels (Fig. 5D). This could be due to cell death occurring in arteries during calcification. By contrast, in response to injury, both SMC proliferation and neointima accumulation were significantly enhanced (Fig. 2). These data suggest that arterial injury is necessary to induce robust neointimal hyperplasia during vitamin D3-mediated medial calcification.

Figure 6. BMP-2 induces proliferation in calcifying but not control SMCs. (A,B) Inorganic phosphate (Pi) induced calcification in MOVAS cells. MOVAS cells were incubated in calcification media (5 mM sodium phosphate and 50 μg/ml sodium ascorbate) for 7 days. Calcification was determined using Alizarin Red S, Von Kossa staining, and alkaline phosphatase activity (AP) staining (A). Calcium content was measured using the o-cresolphthalein complexone method (B). (C,D) BMP-2 increased proliferation in calcifying SMCs. MOVAS cells were incubated in calcification media for 7 days, then starved for 24 h, followed by stimulation with 50 ng/ml BMP-2 or 10 ng/ml PDGF for 36 h. (E,F) Inhibition of BMP blocked BMP-2-mediated proliferation in Pi-treated SMCs. MOVAS cells were incubated in the calcification media for 7 days, then starved for 24 h, followed by stimulation with 50 ng/ml BMP-2 in the absence or presence of BMP inhibitor noggin for 36 h. Proliferation was assessed using Click-IT® EdU Cell proliferation assay. Values are mean ± SD (n = 6). *P < 0.05.
In a second series of experiments, we found that rats with carotid calcification caused by adventitial application of calcium chloride also showed increased intimal accumulation compared with control rats with similar amounts of injury but no calcification. In calcified arteries, medial SMCs showed increased expression of the bone related protein BMP-2 prior to injury. This suggests that the altered milieu present locally in calcifying arteries may predispose to increased amounts of intimal accumulation after balloon injury.

Studies on the effects of BMPs on SMC proliferation and migration have yielded inconsistent results. Initial reports showed that adenoviral BMP-2 over-expression could inhibit neointimal accumulation in a rat carotid injury model, while adding recombinant BMP-2 to cultured SMCs had minimal effect on proliferation in vitro.

It also decreased PDGF-induced proliferation via p21Cip1/Waf1 pathway. And it has been reported that the BMP antagonist Gremlin promotes SMC migration and proliferation. Indeed we have previously shown that BMP decreased PDGF-induced SMC migration but had little effect on proliferation.

More recently, it has been shown that BMP-2 could enhance migration and proliferation of hypoxia-induced SMCs via the Actin/CD44/MMP-2 molecular pathway. Our data suggest that SMCs undergoing calcification related to increased Pi levels show increased sensitivity to BMP stimulation and that this stimulation is effectively blocked by the BMP selective inhibitor Noggin. Together these findings suggest that increased BMP expression in the media of calcifying arteries may serve as a stimulus for increased proliferation after angioplasty procedures.

In conclusion, we have shown that intimal hyperplasia is increased in two different models of medial artery calcification. Calcifying arteries show increased expression of BMP-2, and cells grown in calcifying media exhibit more BMP-induced proliferation than non-calcifying cells. These findings suggest that therapies aimed at preventing restenosis in patients with medial calcification may differ from those developed to prevent it in uncalcified vessels. Future development of such therapies may reduce restenosis and prevent the poor outcomes seen after endovascular interventions in patients with medial artery calcification.

Materials and Methods

Animal procedures. In order to induce medial calcification, male Sprague-Dawley rats weighing 350 to 400 g were injected subcutaneously with 5 mg/kg of Vitamin D₃ for 3 consecutive days. Control rats received vehicle only. All animals were then allowed full access to food and water. At 2 weeks after injections, rats were anesthetized and left carotid balloon injury was performed using a 2Fr Fogarty balloon catheter as previously described.

At 3 weeks following injury, arterial harvest was performed. In a second series of experiments, medial calcification was induced by adventitial application of 0.12 M calcium chloride (CaCl₂) to the exposed left carotid artery and compared with normal saline as a control. Briefly, after animals were anesthetized with Isoflurane, the left carotid artery was exposed via a neck incision and 100 μl CaCl₂ or normal saline was applied to its adventitial surface using a sterile cotton tipped swab. Balloon injury was performed 1 week following CaCl₂ application and arteries were harvested 2 weeks later. For all animals, perfusion fixation was performed with 10% formaldehyde and both the injured left and uninjured right carotid arteries were harvested for histological assessments. All procedures were performed under protocols approved by the Institutional Animal Care and Use Committees of Vanderbilt University Medical Center and Beth Israel Deaconess Hospital. All experiments were performed in accordance with the approved protocols.

Morphometry, immunohistochemistry, and serum analysis. Formalin fixed carotid arteries were embedded in paraffin and cut into 5 μm sections. Von Kossa staining was used to assess calcium deposits on histologic sections by incubating in 1% AgNO₃ for one hour under UV light. Sections were then de-stained with 5% sodium thiosulfate. Nuclear fast red solution (1%) was used for counterstaining. To assess neointimal area, Verhoeff-Van Gieson (VVG) staining was used. Briefly, sections were stained with Verhoeff working solution for 30 minutes then differentiated and de-stained with 2% ferric chloride and 5% sodium thiosulfate. Intimal and medial areas of the arterial specimens were measured using Image J on VVG stained slide sections. The intima to media ratio (I/M ratio) was calculated.

PCNA immunohistochemistry staining was performed to assess cell proliferation using a PCNA kit (Invitrogen, 931143). The Heat-Induced Epitope Retrieval (HIER) method was used for antigen retrieval. Hematoxylin was used for counterstaining. Staining was quantified by counting nuclear brown positive cells in five random fields at 40X magnification field. The PCNA positive cells were counted in both intima and media area within each field and the average was calculated. In separate groups of animals, serum vitamin D₃ levels were measured using the Mouse/Rat 25-OH Vitamin D ELISA Assay Kit, (Eagle Biosciences) and carotid arteries were harvested for IHC staining using an anti-BMP2 antibody (Abcam, ab14933).

Cell culture. Vascular smooth muscle cells (MOVAS, American Type Culture Collection (ATCC, Manassas, VA) were maintained in DMEM (Sigma D6429) supplemented with 10% fetal bovine serum (GIBCO), penicillin (100 U/mL)/streptomycin (0.1 mg/mL) and 0.2 mg/mL L-G418. Cells were cultured at 37 °C in a humidified incubator with 5% CO₂. To induce in calcification in vitro, confluent SMCs were cultured in a calcification medium containing 5.0 mM sodium phosphate and 50 μg/ml sodium ascorbate for 7 days. Cells were then washed twice with PBS, fixed with 10% formaldehyde for 10 min, washed with PBS, and finally stained for 30 min with staining solution (0.1 mg/ml naphthol...
AS-MX, 0.5% N,N-dimethyl formamide, 0.6 mg/ml fast blue BB, 0.1 M Tris-HCl, pH 8.5, 2 mM MgCl₂). Washing with water stopped the reaction.

**Cell proliferation assay.** To investigate the effects of BMP-2 on cell proliferation in calcified and non-calcified MOVAS cells, the Click-IT® EdU Cell proliferation assay (Invitrogen) was performed according to the manufacturer's instruction. Briefly, cells were plated in 4-chamber Culture Slider (BD Falcon), and incubated in calcification media for 7–9 days, then placed in 0.2% BSA-containing media for 24 h to induce quiescence. Next, cells were treated with 50 ng/ml BMP-2 (R&D Systems) for 36 h. For positive controls, cells were stimulated with 40 ng/ml PDGF-BB (R&D Systems). In inhibition experiments, the BMP inhibitor Noggin (R&D Systems) was added to inhibit BMP-2 activity. Cells were then labeled with 15μM EdU, fixed with 3.7% formaldehyde, and made permeable with 0.5% Triton X-100. EdU in cells was detected through the reaction with Alexa Fluor® 594 azide. Nuclei were counterstained with DAPI. The fluorescence images were separately taken at Alexa Fluor® 594 and DAPI channels on a Leica fluorescence-imaging microscope. The image of each channel was quantified by measuring the fluorescence area with Adobe Photoshop. The cell proliferation rate was presented as the ratio of EdU channel to DAPI/Hoechst channel fluorescence.

**Data analysis.** Statistics were performed using GraphPad Prism. One-way ANOVA with Bonferroni’s multiple comparisons test and t-test were used for data analysis. The data were graphed and analyzed using GraphPad Prism®. Unpaired t-test between the IM ratio of treated and vehicle samples was used for data analysis.

**Data Availability**

The datasets generated during the current study are available from the corresponding author on reasonable request.

**References**

1. Bangalore, S., Guo, Y., Samadashvili, Z., Blecker, S. & Hanan, E. L. Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery. *Circulation*. 133, 2132–40 (2016).

2. Kimlay, S. Management of Critical Limb Ischemia. *Circulation Cardiovascular interventions*. 9, e01946 (2016).

3. Kufner, S. et al. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. *Cardiovascular revascularization medicine: including molecular interventions*. 15, 69–75 (2014).

4. Iida, O. et al. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions. *JACC Cardiovascular interventions*. 9, 828–34 (2016).

5. Lo, R. C. et al. Outcomes following infrapopliteal angioplasty for critical limb ischemia. *Journal of vascular surgery*. 57, 1455–63; discussion 1463–4 (2013).

6. Nishida, K. et al. Comparison of outcomes using the sirolimus-eluting stent in calcified versus non-calcified native coronary lesions in patients on- versus not-on chronic hemodialysis (from the Cypher registry). *The American journal of cardiology*. 112, 464–5 (2013).

7. Tanabe, K. et al. Impact of coronary calcium on outcome following sirolimus-eluting stent implantation. *The American journal of cardiology*. 108, 514–7 (2011).

8. Onuma, Y. et al. Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. *Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions*. 76, 634–42 (2010).

9. Bakken, A. M. et al. Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions. *Journal of vascular surgery*. 46, 946–958; discussion 958 (2007).

10. London, G. M. Arterial calcification: cardiovascular function and clinical outcome. *Nefrologia: publicacion oficial de la Sociedad Española Nefrologia*. 31, 644–7 (2011).

11. Demer, L. L. & Tintut, Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. *Arteriosclerosis, thrombosis, and vascular biology*. 34, 715–23 (2014).

12. Chowdhury, M. M. et al. Lower limb arterial calcification (LLAC) scores in patients with symptomatic peripheral arterial disease are associated with increased cardiac mortality and morbidity. *Plos one*. 12, e0182952 (2017).

13. Zhang, M. et al. BMP-2 overexpression augments vascular smooth muscle cell motility by upregulating myosin Va via Erk signaling. *Oxidative medicine and cellular longevity*. 2014, 294150 (2014).

14. Willette, R. N. et al. BMP-2 gene expression and effects on human vascular smooth muscle cells. *Journal of vascular research*. 36, 120–5 (1999).

15. Dorai, H., Vukicevic, S. & Sampath, T. K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. *Journal of cellular physiology*. 184, 37–45 (2000).

16. Corriere, M. A. et al. Endothelial BMP4 is induced during arterial remodeling: effects on smooth muscle cell migration and proliferation. *The journal of surgical research*. 145, 142–9 (2008).

17. Maciel, T. T., Melo, R. S., Schor, N. & Campos, A. H. Gremlin promotes vascular smooth muscle cell proliferation and migration. *Journal of molecular and cellular cardiology*. 44, 370–9 (2008).

18. Nahar-Gohad, P., Gohad, N., Tsai, C. C., Bordia, R. & Vyavahare, N. Rat aortic smooth muscle cells cultured on hydroxyapatite differentiate into osteoblast-like cells via BMP-2-SMAD-5 pathway. *Calcified tissue international*. 96, 359–69 (2015).

19. Ho, C. Y. & Shanahan, C. M. Medial Arterial Calcification: An Overlooked Player in Peripheral Arterial Disease. *Arteriosclerosis, thrombosis, and vascular biology*. (2016).

20. Cardus, A. et al. 1,25-Dihydroxyvitamin D₃ stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. *Kidney international*. 69, 1377–84 (2006).

21. Yamamoto, T. et al. 1,25-dihydroxyvitamin D₃ stimulates vascular endothelial growth factor release in aortic smooth muscle cells: role of p38 mitogen-activated protein kinase. *Archives of biochemistry and biophysics*. 398, 1–6 (2002).

22. Qin, X., Corriere, M. A., Matrisian, L. M. & Guzman, R. J. Matrix metalloproteinase inhibition attenuates aortic calcification. *Arteriosclerosis, thrombosis, and vascular biology*. 26, 1510–6 (2006).

23. Fujimoto, H., Nakamura, M. & Yokoi, H. Impact of calcification on the long-term outcomes of sirolimus-eluting stent implantation: subanalysis of the Cypher Post-Marketing Surveillance Registry. *Circulation journal: official journal of the Japanese Circulation Society*. 76, 57–64 (2012).

24. Allgrove, J. Physiology of Calcium, Phosphate, Magnesium and Vitamin D. *Endocrine development*. 28, 7–32 (2015).
25. Niederhoffer, N., Bobryshev, Y. V., Lartaud-Idjouadiene, I., Guimelly, P. & Atkinson, J. Aortic calcification produced by vitamin D3 plus nicotine. *Journal of vascular research*. **34**, 386–98 (1997).
26. Niederhoffer, N. *et al.* Calcification of medial elastic fibers and aortic elasticity. *Hypertension (Dallas, Tex)*. **29**, 999–1006 (1997).
27. Lamawansa, M. D., Wysocki, S. J., House, A. K. & Norman, P. E. Vitamin D3 exacerbates intimal hyperplasia in balloon-injured arteries. *The British journal of surgery*. **83**, 1101–3 (1996).
28. Mitsuhashi, T., Morris, R. C. Jr. & Ives, H. E. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. *The Journal of clinical investigation*. **87**, 1889–95 (1991).
29. Koh, E. *et al.* 1,25-Dihydroxyvitamin D3 binds specifically to rat vascular smooth muscle cells and stimulates their proliferation in vitro. *Life sciences*. **42**, 215–23 (1988).
30. Koh, E. *et al.* Effects of 1,25-dihydroxyvitamin D3 on the syntheses of DNA and glycosaminoglycans by rat aortic smooth muscle cells in vitro. *Life sciences*. **46**, 1545–51 (1990).
31. Tukaj, C., Trzonkowski, P., Kubasik-Juraniec, J. & Mysliwski, A. Quantifying division of aortal smooth muscle cells in culture stimulated by 1,25(OH)2D3. *The Journal of steroid biochemistry and molecular biology*. **103**, 525–8 (2007).
32. Tukaj, C. & Wrzolkowa, T. Effects of vitamin D on aortic smooth muscle cells in culture. *Toxicology in vitro: an international journal published in association with BIBRA*. **10**, 701–11 (1996).
33. Carthy, E. P., Yamashita, W., Hsu, A. & Ooi, B. S. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. *Hypertension (Dallas, Tex)*. **13**, 954–9 (1989).
34. Chen, S., Law, C. S. & Gardner, D. G. Vitamin D-dependent suppression of endothelin-induced smooth muscle cell proliferation through inhibition of CDK2 activity. *The Journal of steroid biochemistry and molecular biology*. **118**, 135–41 (2010).
35. Chen, S., Law, C. S., Grigsby, C. L., Olsen, K. & Gardner, D. G. A role for the cell cycle phosphatase Cdc25a in vitamin D-dependent inhibition of adult rat vascular smooth muscle cell proliferation. *The Journal of steroid biochemistry and molecular biology*. **122**, 326–32 (2010).
36. Rebsamen, M. C., Sun, J., Norman, A. W. & Liao, J. K. 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. *Circulation research*. **91**, 17–24 (2002).
37. Nakaoaka, T. *et al.* Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2. *The Journal of clinical investigation*. **100**, 2824–32 (1997).
38. Wong, G. A., Tang, V., El-Sabawy, F. & Weiss, R. H. BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1. *American journal of physiology Endocrinology and metabolism*. **284**, E972–9 (2003).
39. Yang, M. *et al.* BMP-2 enhances the migration and proliferation of hypoxia-induced VSMCs via activin cytoskeleton, CD44 and matrix metalloproteinase linkage. *Experimental cell research*. **368**, 248–257 (2018).
40. Clowes, A. W., Reidy, M. A. & Clowes, M. M. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. *Laboratory investigation; a journal of technical methods and pathology*. **49**, 327–33 (1983).
41. Connerty, H. V. & Briggs, A. R. Determination of serum calcium by means of orthocresolphthalein complexone. *Am J Clin Pathol*. **45**, 290–6 (1966).

**Acknowledgements**

This work was supported in part by grants T32 DK00706 (A.P.M.) and an NIH grant R01 HL105641 (R.J.G.).

**Author Contributions**

A.P.M. and W.L. contributed equally to the experimental data collection and wrote the first drafts of the manuscript. X.W. and T.L. assisted with data analysis. Y.C. assisted with experimental design and contributed to the final drafting of the manuscript. R.G. participated in experimental design, data analysis, and writing of the final manuscript. He was responsible for overseeing all aspects of this research.

**Additional Information**

**Competing Interests:** The authors declare no competing interests.

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019